Document:

<PAGE>

                                                                    EXHIBIT 10.6

[CONFIDENTIAL TREATMENT REQUESTED, CONFIDENTIAL PORTIONS OF THIS AGREEMENT HAVE
BEEN REDACTED AND HAVE BEEN SEPARATELY FILED WITH THE COMMISSION.]

                         TECHNOLOGY PURCHASE AGREEMENT

         This TECHNOLOGY PURCHASE AGREEMENT (this "Agreement") is entered into
                                                   ---------
as of October 10, 2000 (the "Effective Date") by and between, TheraSense, Inc.,
                             --------------
a California corporation ("Purchaser"), and E. Heller & Company, a Texas
                           ---------
corporation ("Seller"), (Purchaser and Seller each, a "Party;" together, the
              ------                                   -----
"Parties" ).
 -------
                                   RECITALS

          WHEREAS, Purchaser wishes to acquire from Seller, and Seller wishes to
sell to Purchaser, the biosensor-related technologies of Seller; and

          WHEREAS, ***

          NOW, THEREFORE, in consideration of the foregoing and of the mutual
promises contained in this Agreement, the Parties hereby agree as follows:

                                   ARTICLE 1
                                  DEFINITIONS

          1.1  Capitalized Terms. The following capitalized terms shall have the
meanings set forth below :

               (a)  "Affiliate" shall mean any entity which controls, is
                     ---------
controlled by or is under common control with a Party, but only so long as such
control exists. For purposes of this definition, "control" shall mean direct or
indirect ownership of more than fifty percent (50%) of the shares of the
respective entity entitled to vote in the election of directors (or, in the case
of a Person that is not a corporation, for the election of the corresponding
managing authority).

               (b)  "Business" shall mean the development, manufacture and sale
                     --------
of electrochemical biosensors and wired enzyme chemistry.

               (c)  "Competition" shall mean any Person engaged in the Business
                     -----------
or in the business of manufacturing, producing or selling medical devices
related to diabetes.

               (d)  "Current Products" shall mean the Purchaser's FreeStyle
                     ----------------
products and continuous glucose monitoring system under development (as embodied
in the current prototype of such system).

               (e)  "EHC-TheraSense Agreement" shall mean the license agreement
                     ------------------------
between Seller and Purchaser, dated April 21, 1997.

               (f)  "Exclusive Period" shall mean the period beginning on the
                     ----------------
Effective Date and ending thirty-six (36) months following the Effective Date.

*** Confidential treatment requested.
<PAGE>

               (g) "Geographic Area" shall mean the United States, Canada,
                    ---------------
Europe or Japan.

               (h) "Intellectual Property Rights" shall mean, with respect to
                    ----------------------------
the Transferred Technologies, any or all of the following and all statutory
and/or common law rights throughout the world in, arising out of, or associated
therewith: (i) all patents and applications therefor and all reissues,
divisions, renewals, extensions, provisionals, continuations and continuations-
in-part thereof; (ii) all inventions (whether patentable or not patentable,
copyrightable or not copyrightable), invention disclosures and improvements
thereto, (iii) all trade secrets and proprietary information relating thereto;
(iv) all algorithms, routines, schematics, works of authorship, copyrights, mask
works, copyright and mask work registrations and applications; (v) all files,
databases and data collections (including knowledge databases, customer lists
and customer databases); (vi) all rights in Software; (vii) all rights in
Materials, (viii) all similar, corresponding or equivalent rights to any of the
foregoing; (ix) all goodwill associated with any of the foregoing; and (x) all
rights to any tangible embodiments of any of the foregoing.

               (i)  "Know How" shall mean all ideas, know how, show-how,
                     --------
techniques, design rules, data, instructions, protocols, methods, processes,
formulas and test methodologies, including without limitation biological,
chemical, toxicological, physical and analytical, safety, manufacturing and
quality control data and information necessary and/or useful to develop and/or
commercialize the Intellectual Property Rights.

               (j)  "Liability" shall mean any liability or obligation (whether
                     ---------
known or unknown, whether asserted or unasserted, whether absolute or
contingent, whether accrued or unaccrued, whether liquidated or unliquidated,
whether incurred or consequential and whether due or to become due), including
any liability for taxes.

               (k)  "Lien" shall mean any mortgage, pledge, lien, security
                     ----
interest, charge, claim, equity, encumbrance, restriction on transfer,
conditional sale or other title retention device or arrangement (including,
without limitation, a capital lease), transfer for the purpose of subjection to
the payment of any indebtedness, or restriction on the creation of any of the
foregoing, whether relating to any property or right or the income or profits
therefrom.

               (l)  "Materials" shall mean any and all (i) chemical or
                     ---------
biological substances, including without limitation any organic or inorganic
chemical element, compound, composition, material, sample or product; (ii)
assays or reagents; (iii) fragments of (i) and/or (ii); (iv) any derivatives,
variants or mutations of (i) through (iii); (v) any DNA, protein or chemical
sequence of (i) through (iv); (vi) instruments, devices, prototypes, hardware,
development tools, or components of any of the foregoing; and (vii) tangible
embodiments of Intellectual Property Rights.

               (m)  ***

               (n)  "Person" shall mean an individual, partnership, corporation,
                     ------
association, joint venture, trust, unincorporated organization or governmental
entity (or any department, agency or political subdivision thereof).

*** Confidential treatment requested

                                      -2-
<PAGE>

               (o)  "Purchaser Claim" shall mean any claim, suit or proceeding
                     ---------------
commenced against Purchaser.

               (p)  "Registered IP" shall mean all United States, international
                     -------------
and foreign: (i) patents and patent applications (including provisional
applications) or service marks related to the Business; and (ii) any other
Intellectual Property Rights related to the Business that are the subject of an
application, certificate, filing, registration or other document issued, filed
with, or recorded by any state, government or other public legal authority.

               (q)  "Seller Claim" shall mean any claim, suit or proceeding
                     ------------
commenced against Seller.

               (r)  "Software" shall mean all computer system software,
                     --------
including without limitation all source code, object code, upgrades, updates,
bug fixes, releases and supporting documentation relating thereto.

               (s)  "Transaction" shall mean the transaction contemplated by
                     -----------
this Agreement.

               (t)  ***

               (u)  ***

                                   ARTICLE 2
                              TRANSFER OF ASSETS
                              ------------------

          2.1 Sale of Technologies. Seller hereby sells, conveys, transfers, and
              --------------------
assigns to Purchaser all rights, title and interest in the assets set forth in
Schedule 2.1(a), including, without limitation, any Intellectual Property
---------------
Rights, Know How, Registered IP Software and Materials owned or controlled by
Seller and related thereto, but specifically excluding those assets set forth in
Schedule 2.1(b) (the "Excluded Assets") (collectively, the "Transferred
---------------       ---------------                       -----------
Technologies"). To the best knowledge of Seller, Seller has no Software of
------------
Materials as of the Effective Date .

          2.2 Assumed Liabilities. Purchaser hereby assumes and becomes
              -------------------
responsible for all of the Liabilities set forth on Schedule 2.2 (the "Assumed
                                                                       -------
Liabilities").

          2.3 Excluded Liabilities. Excepts as provided in Section 6.3,
              --------------------                         -----------
Purchaser does not assume or have any responsibility with respect to any
Liabilities of the Seller not set forth on Schedule 2.2. Without limiting the
                                           ------------
generality of the foregoing, there shall not be sold, assigned, transferred or
delivered hereunder, and the terms "Transferred Technologies" and "Assumed
Contracts" does not include any of the Liabilities set forth on Schedule 2.3 or
                                                                ------------
those associated with the Excluded Assets (the "Excluded Liabilities").
                                                --------------------
          2.4 Termination of EHC-TheraSense Agreement. The EHC-TheraSense
              ---------------------------------------
Agreement is hereby terminated.

*** Confidential treatment requested.

                                      -3-
<PAGE>

           2.5 Delivery of Transferred Technologies. Seller, in the manner and
               ------------------------------------
form, and to the locations, reasonably specified by Purchaser, hereby delivers
to Purchaser all of the Transferred Technologies, or other intangible assets and
such instruments as are necessary or desirable to transfer title to such assets
from Seller to Purchaser.

          2.6  Books and Records. Seller hereby transfers to Purchaser all
               -----------------
books, records, files and related materials in respect of the Transferred
Technologies in Seller's possession. Such books, records, files and related
materials constitute all of the books, records, files and related materials in
respect of the Transferred Technologies created or maintained by Seller.

          2.7  Agreement to Perform Necessary Acts. Seller shall take all action
               -----------------------------------
as may be reasonably necessary, proper or advisable to put Purchaser in
ownership, possession, and operating control of the Transferred Technologies,
without demanding any further consideration therefor, including execution,
acknowledgment and recordation of specific assignments, oaths, declarations and
other documents on a country-by-country basis and such other instruments of
sale, transfer, conveyance, and assignment as Purchaser or its counsel may
reasonably request.

          2.8  Power of Attorney. Seller hereby grants Purchaser the irrevocable
               -----------------
power of attorney to represent Seller, where such representation is legally
permissible, without restrictions towards legal entities and natural persons,
public authorities and courts, to do, sign under hand (or, as required, under
personal seal), deliver, receive and perform all and any acts, matters,
statements and things which may be necessary to put the Purchaser in ownership,
possession, and operating control of the Transferred Technologies, including
execution, acknowledgment and recordation of specific assignments, oaths,
declarations and other documents on a country-by-country basis and such other
instruments of sale, transfer, conveyance, and assignment as may be required for
this purpose. Under this power of attorney, the Purchaser is entitled to enter
into transactions on behalf of Seller with itself in its own name or in its
capacity as attorney-in-fact of a third party and, therefore, the Purchaser is
released from any prohibition or restriction of self dealing which may exist
under any applicable law. The Purchaser shall be entitled to delegate the rights
granted to it by this power-of-attorney and to grant dispensation from any legal
prohibition or restriction of self dealing which may exist. The foregoing power
of attorney is coupled with an interest and as of the Effective Date shall be
irrevocable.

                                   ARTICLE 3
                                PAYMENT; TAXES
                                --------------

          3.1 Payment to Seller. Purchaser shall pay an aggregate of *** (the
              -----------------
"Purchase Price") by check or wire transfer to a bank account of Seller
 --------------
specified in writing.

          3.2 Taxes. Seller shall be solely responsible for the payment of, and
              -----
shall pay when due, any taxes that may be payable in connection with the sale of
the Transferred Technologies or the granting of the licenses granted hereunder,
other than taxes assessed on Purchaser's income.

*** Confidential treatment requested.
                                      -4-
<PAGE>

                                   ARTICLE 4
                        REPRESENTATIONS AND WARRANTIES
                        ------------------------------

          Seller represents and warrants to Purchaser, subject to such
exceptions as are specifically set forth in the disclosure schedule (referencing
the appropriate Section and paragraph numbers) attached hereto (the "Disclosure
                                                                     ----------
Schedule") and dated as of the date hereof, as follows:
--------

          4.1  Authorization of Transaction. Seller has all requisite power and
               ---------------------------
authority to enter into this Agreement and any related agreements to which it is
a Party and to consummate the transactions contemplated hereby and thereby. The
execution and delivery of this Agreement and the consummation of the
transactions contemplated hereby have been duly authorized by all necessary
corporate action on the part of Seller, and no further actions are required on
the part of Seller or any of its stockholders to authorize the Agreement, any
related agreements to which it is a Party and the transactions contemplated
hereby.

          4.2  Noncontravention. The execution and delivery of this Agreement by
               ----------------
Seller and the consummation of the transactions contemplated hereby and thereby
do not conflict with, or result in any violation of, or default under (with or
without notice or lapse of time, or both), or give rise to a right of
termination, cancellation, modification or acceleration of any obligation or
loss of any benefit under (any such event, a "Conflict") (i) any provision of
                                              --------
the charter documents or bylaws (or like document) of Seller, (ii) any mortgage,
lease, indenture, contract or other agreement or instrument, permit, concession,
franchise or license to which Seller is a Party or any of its properties or
assets are subject, (iii) any judgment, order, decree, statute, law, ordinance,
rule or regulation applicable to Seller or its properties or assets.

          4.3  Restrictions on Transaction. There is no agreement (not to
               ---------------------------
compete or otherwise), commitment, judgment, injunction, order or decree to
which Seller is a Party or otherwise binding upon Seller which has or may have
the effect of prohibiting the Transaction or impairing the Transferred
Technologies. Seller has not entered into any agreement which places any
restrictions upon Seller with respect to the Transferred Technologies.

          4.4  Title to Transferred Technologies; Absence of Liens and
               -------------------------------------------------------
Encumbrances; Condition. Seller has good and valid title to all of the
-----------------------
Transferred Technologies, and the power to sell the Transferred Technologies
free and clear of any Liens. There are no other rights, options or licenses
granted pursuant to the Transferred Technologies other than those set forth on
Schedule 4.4. The Transferred Technologies are all of the technologies and
------------
rights, which are presently used, and are reasonably necessary for use in the
Current Products.

          4.5  Intellectual Property Rights. To the knowledge of Seller as of
               ----------------------------
the Effective Date, Seller owns, or possesses adequate licenses or other rights
to use, any and all Intellectual Property Rights used in or related to the
Transferred Technologies as used in the Current Products. Seller has not
received written notice of any claims, disputes, actions, proceedings, suits or
appeals pending against Seller with respect to any Intellectual Property Rights
or any other adverse consequences with respect to any Intellectual Property
Rights that would reasonably be expected to have a material adverse effect on
the Transferred Technologies, and, to the knowledge of Seller, none has been
overtly threatened. To the best knowledge of Seller as of the Effective Date,
except

                                      -5-
<PAGE>

pursuant to licenses obtained by Purchaser, none of the products or processes
using the Intellectual Property Rights as used in the Current Products infringes
on the proprietary rights of any third party, no product (or component thereof)
or process used by, sold or manufactured for, or supplied to, Seller or
Purchaser infringes or otherwise violates the proprietary rights of any other
Person. Except as set forth on Schedule 4.4, Seller has not granted any Person
                               ------------
the right to use the Intellectual Property Rights.

          4.6  Litigation. To the best knowledge of Seller, other than those
               ----------
related to prosecution of the Seller's Registered IP, there are no judicial or
administrative actions, claims, suits, proceedings or investigations pending or
threatened relating to the Transferred Technologies, nor is there any basis for
any such action, claim, suit, proceeding or investigation. There are no
judgments, orders, decrees, citations, fines or penalties heretofore assessed
against Seller affecting the Transferred Technologies under any foreign,
federal, state or local law.

          4.7  Disclosure. All information furnished by Seller to *** or
               ----------
Purchaser and contained in the *** was and is accurate, complete and
correct and reflects all material discussions and understandings with respect to
the matters set forth therein.

                                   ARTICLE 5
                  REPRESENTATIONS AND WARRANTIES OF PURCHASER
                  -------------------------------------------

         Purchaser represents and warrants to Seller as follows:

          5.1  Organization of Purchaser. Purchaser is duly organized, validly
               -------------------------
existing, and in good standing under the laws of the jurisdiction of its
incorporation or formation.

          5.2  Authority for Agreement. Purchaser has all requisite corporate
               -----------------------
power and authority to enter into this Agreement and the related agreements to
which it is a Party and to consummate the transactions contemplated hereby and
thereby. The execution and delivery of this Agreement and the related agreements
and the consummation of the transactions contemplated hereby and thereby have
been duly authorized by all necessary corporate action on the part of Purchaser.
This Agreement has been duly executed and delivered by Purchaser and
constitutes, and the related agreements, when duly executed and delivered by
Purchaser, will constitute the valid and binding obligations of Purchaser,
enforceable in accordance with their terms.

          5.3  Noncontravention. Neither the execution and the delivery of this
               ----------------
Agreement, nor the consummation of the transactions contemplated hereby, will
(i) violate any provision of the charter or bylaws of Purchaser or (ii) Conflict
with any material agreement, contract, lease, license, instrument, or other
arrangement to which Purchaser is a Party or by which it is bound or to which
any of its assets is subject except for such Conflicts which would not, either
individually or in the aggregate, have a material adverse effect on Purchaser.

                                   ARTICLE 6
                         SURVIVAL OF REPRESENTATIONS,
                         ---------------------------
                        WARRANTIES AND INDEMNIFICATION
                        ------------------------------

          6.1  Survival of Representations and Warranties. All of the
               ------------------------------------------
representations and warranties of Seller and Purchaser contained herein shall
survive the Effective Date and continue in

*** Confidential treatment requested.

                                      -6-
<PAGE>

full force and effect until 5:00 p.m., Pacific Time, sixty (60) months following
the Effective Date (the "Indemnity Period").

          6.2  Indemnification of Purchaser. Seller agrees to indemnify and hold
               ----------------------------
Purchaser and its officers, directors and Affiliates harmless against all
claims, losses, liabilities, damages, deficiencies, costs and expenses,
including reasonable attorneys' fees and expenses, and expenses of investigation
and defense (including, without limitation, any consequential damages)
(hereinafter individually a "Loss" and collectively "Losses"), incurred or
                             ----                    ------
suffered by Purchaser or its officers, directors, or Affiliates directly or
indirectly as a result of (i) any inaccuracy or breach of a representation or
warranty of Seller; (ii) any failure by Seller to perform or comply with any
covenant contained herein; (iii) any liabilities of Seller not specifically
assumed by Purchaser, or any liabilities in connection with the Transferred
Technologies, arising from Seller's actions or omissions prior to the Effective
Date; provided, that such Loss occurs during the Indemnity Period and Purchaser
      --------
provides Seller with notice of a Purchaser Claim under the foregoing indemnity
within twenty-four (24) months of the Effective Date.

          6.3  Indemnification of Seller. Purchaser agrees to indemnify and hold
               -------------------------
Seller and its officers, directors and Affiliates harmless against all Losses
incurred or suffered by Seller or its officers, directors or Affiliates directly
or indirectly as a result of (i) any inaccuracy or breach of a representation or
warranty of Purchaser; (ii) any liabilities in connection with the Transferred
Technologies arising from Purchaser's actions or omissions after the Effective
Date; and (iii) ***; provided, that such Loss occurs during the Indemnity Period
                     --------
and Seller provides Purchaser with notice of a Seller Claim under the foregoing
indemnity within twenty-four (24) months of the Effective Date.

          6.4  Third-Party Claims to Purchaser. In the event Purchaser becomes
               -------------------------------
aware of a third-party claim that Purchaser believes may result in Losses,
Purchaser shall notify Seller of such claim and Seller shall be entitled, at its
expense, to participate in, but not to determine or conduct, the defense of such
claim. Purchaser shall have the right in its sole discretion to conduct the
defense of and settle any such claim; provided, however, that unless such
                                      --------  -------
settlement is made with the written consent of Seller, no settlement of any such
claim with third-party claimants shall be determinative of the amount of any
claim for indemnification pursuant to Section 6.2 or whether such claim
                                      -----------
constitutes a Loss as defined in Section 6.2. In the event Seller has consented
                                 -----------
to any such settlement, Seller shall have no power or authority to object under
any provision of this Section 6.4 to the amount of any claim by Purchaser with
                      -----------
respect to such settlement.

          6.5  Third-Party Claims to Seller. In the event Seller becomes aware
               ----------------------------
of a third-party claim that Seller believes may result in Losses, Seller shall
notify Purchaser of such claim and Purchaser shall be entitled, at its expense,
to participate in, but not to determine or conduct, the defense of such claim.
Seller shall have the right in its sole discretion to conduct the defense of and
settle any such claim; provided, however, that unless such settlement is made
                       --------  -------
with the written consent of Purchaser, no settlement of any such claim with
third-party claimants shall be determinative of the amount of any claim for
indemnification pursuant to Section 6.3 or whether such claim constitutes a Loss
                            -----------
as defined in Section 6.3. In the event Purchaser has consented to any such
              -----------
settlement, Purchaser shall have no power of authority to object under any
provision of this Section 6.5 to the amount of any claim by Seller with respect
                  -----------
to such settlement.

                                      -7-
<PAGE>

                                   ARTICLE 7
                                   COVENANTS
                                   ---------

          7.1  Additional Documents and Further Assurances. Each Party, at the
               -------------------------------------------
request of another Party, shall execute and deliver such other instruments and
do and perform such other acts and things as may be necessary or desirable for
effecting completely the consummation of this Agreement and the transactions
contemplated hereby.

          7.2  Non-Competition Obligation.
               --------------------------

               (a) During the Exclusive Period and within the Geographic Area,
Seller shall not directly or indirectly, without the prior written consent of
Purchaser, (i) have any ownership interest in (except for passive ownership of
five percent (5%) or less of an entity whose securities are publicly traded) any
Competition and excluding any ownership in Purchaser or any successor entity,
(ii) participate in the financing, operation, management or control, or assist
in or support the development of any Competition or (iii) license any
Intellectual Property Rights or technology to any Competition.

               (b) The covenants contained in Section 7.2(a) shall be construed
                                              --------------
as a series of separate covenants, one for each county, city, state and country
of the Geographic Area. Except for geographic coverage, each such separate
covenant shall be deemed identical in terms to the covenant contained in Section
                                                                         -------
7.2(a). If, in any judicial proceeding, a court refuses to enforce any of such
------
separate covenants (or any part thereof), then such unenforceable covenant (or
such part) shall be eliminated from this Agreement to the extent necessary to
permit the remaining separate covenants (or portions thereof) to be enforced. In
the event that the provisions of this Section 7.2 are deemed to exceed the time,
                                      -----------
geographic or scope limitations permitted by applicable law, then such
provisions shall be reformed to the maximum time, geographic or scope
limitations, as the case may be, permitted by applicable laws.

               (c) Seller acknowledges that (i) the goodwill associated with the
Business and customer relationships prior to the Transaction is an integral
component of the value of the Business, including the Transferred Technologies,
to Purchaser and is reflected in the Purchase Price for the Transaction to be
received by Seller, (ii) Seller agreements as set forth herein are necessary to
preserve the value of the acquired Business including their goodwill and
customer relationships, for Purchaser following the Transaction and (iii)
Seller's covenants as set forth in Section 7.2(a) are necessary to preserve the
                                   --------------
value of the Transaction for Purchaser following the Effective Date.

               (d) Seller agrees that it may be impossible or inadequate to
fully measure and calculate Purchaser damages from any breach of the covenants
set forth in Section 7.2(a). Accordingly, Seller agrees that if it breaches or
             --------------
threatens to breach any provision of Section 7.2(a), Purchaser shall be entitled
                                     --------------
to, in addition to any other right or remedy otherwise available, an injunction
from a court of competent jurisdiction restraining such breach or threatened
breach and to specific performance of such provision of this Agreement. Seller
further agrees that no bond or other security shall be required of Purchaser in
obtaining such equitable relief, nor will proof of irreparable harm be required
for such equitable relief. Seller hereby expressly consents to the issuance of
such injunctive relief, whether in the form of a temporary restraining order or
otherwise, and to the ordering of such specific performance.

                                      -8-
<PAGE>

               (e) The provisions of this Section 7.2 shall not apply to Ephraim
                                          -----------
Heller as an individual; provided, however, that nothing contained in this
                         --------  -------
Agreement shall effect the duties, rights or obligations of Mr. Heller or
Purchaser under any arrangements or agreements between Mr. Heller and Purchaser.

          7.3  Solicitation of Employees. Seller agrees that for a period of
               -------------------------
thirty-six (36) months following the date hereof, Seller will not hire any
employees of Purchaser and will not either directly or indirectly, solicit,
induce, recruit or encourage any of the Purchaser's employees to leave their
employment, or take away such employees, or attempt to solicit, induce, recruit,
encourage or take away employees of the Purchaser, either for Seller or any
other person or entity.

          7.4  Termination of ***. Seller agrees that it shall use reasonable
               ------------------
efforts to terminate, in writing, *** within ten (10) days of the Effective
Date.
                                   ARTICLE 8
                                    GENERAL
                                    -------

          8.1  No Agency. Except as expressly provided herein, each Party shall
               ---------
in all matters relating to this Agreement act as an independent contractor.
Neither Party shall have authority, nor shall either Party represent that it has
any authority, to assume or create any obligation, express or implied, on behalf
of the other, or to represent the other Party as agent or employee or in any
other capacity. Neither execution nor performance of this Agreement shall be
construed to have established any agency, joint venture, or partnership.

          8.2  Fees and Expenses. All expenses, including without limitation all
               -----------------
legal, accounting, financial advisory, consulting and other fees, incurred in
connection with the negotiation or effectuation of this Agreement or
consummation of the Transaction, shall be the obligation of the respective Party
incurring such expenses.

          8.3  Notices. Any notice or other communication required or permitted
               -------
to be delivered to any Party under this Agreement must be in writing and shall
be deemed properly delivered, given and received when delivered (by hand, by
registered mail, by courier or express delivery service or by facsimile) to the
address or facsimile telephone number set forth beneath the name of such Party
below (or to such other address or facsimile telephone number as such Party may
have specified in a written notice given to the other Party):

                  if to Purchaser:          TheraSense, Inc.
                                            1360 South Loop Road
                                            Alameda, CA 94502
                                            Attn:  Chief Financial Officer
                                            Telephone:  (510) 749-5400
                                            Facsimile:  (510) 749-5401

*** Confidential treatment requested

                                      -9-
<PAGE>

                  with a copy to:           Wilson Sonsini Goodrich & Rosati
                                            Professional Corporation
                                            One Market, Spear Street Tower
                                            San Francisco, California 94105
                                            Attn:  Karen A. Dempsey
                                            Telephone:  (415) 947-2000
                                            Facsimile:  (415) 947-2099

                   if to Seller:            E. Heller & Company
                                            1360 South Loop Road
                                            Alameda, CA  94502
                                            Attn:  Ephraim Heller, President
                                            Telephone:  (510) 749-5411
                                            Facsimile:  (510) 749-5461

                  with a copy to:           Ropers, Majeski, Kohn & Bentley
                                            1001 Marshall Street
                                            Redwood City, CA 94063
                                            Attn:  Francois Laugier
                                            Telephone:  (650) 780-1691
                                            Facsimile:  (650) 780-1606

          8.4  Governing Law. This Agreement shall be governed in all respects
               -------------
by the laws of the United States of America and the State of California as such
laws apply to agreements entered into and to be performed entirely within
California by California residents.

          8.5  Forum and Venue. Any judicial action or proceeding arising
               ---------------
hereunder or relating hereto shall be brought in, and the Parties hereby consent
to the exclusive, personal jurisdiction of, the state and federal courts located
in Santa Clara, California. Seller hereby consents to the jurisdiction of such
courts and hereby appoints its counsel identified in Section 8.3 as its agent
for service of process.

          8.6  Breaches and Remedies. Except as otherwise provided herein, any
               ---------------------
and all remedies herein expressly conferred upon a Party will be deemed
cumulative with and not exclusive of any other remedy conferred hereby, or by
law or equity upon such Party, and the exercise by a Party of any one remedy
will not preclude the exercise of any other remedy.

          8.7  Waiver. No failure on the part of a Party to exercise any power,
               ------
right, privilege, or remedy under this Agreement, and no delay on the part of
any Party in exercising any power, right, privilege, or remedy under this
Agreement, will operate as a waiver of such power, right, privilege, or remedy;
and no single or partial exercise of any such power, right, privilege, or remedy
will preclude any other or further exercise thereof or of any other power,
right, privilege, or remedy. No Party shall be deemed to have waived any claim
arising from this Agreement, or any power, right, privilege or remedy under this
Agreement, unless the waiver of such claim, power, right, privilege or remedy is
expressly set forth in a written instrument duly executed and delivered on
behalf of such Party; and any such waiver will not be applicable or have any
effect except in the specific instance in which it is given.

                                      -10-
<PAGE>

          8.8  Assignment. Purchaser may assign all of its assets, licenses and
               ----------
other rights acquired hereunder in their entirety or in part prior to or after
the Effective Date in connection with a sale of substantially all assets of
Purchaser or in connection with merger solely for purposes of reincorporation.

          8.9  Severability. If, for any reason, a court of competent
               ------------
jurisdiction finds any provision of this Agreement, or portion thereof, to be
invalid or unenforceable, such provision of the Agreement will be enforced to
the maximum extent permissible so as to effect the intent of the Parties, and
the remainder of this Agreement will continue in full force and effect. The
Parties agree to negotiate in good faith an enforceable substitute provision for
any unenforceable provision that most nearly achieves the intent and economic
effect of the unenforceable provision. Notwithstanding the foregoing, if a court
of competent jurisdiction determines that any restriction on any license granted
herein is invalid or unenforceable, then the license grants to which such
restriction relates shall terminate automatically.

          8.10 Entire Agreement. This Agreement (including the Schedules and
               ----------------
Exhibits hereto) sets forth the entire understanding of the Parties hereto
relating to the subject matter hereof and supersedes all prior agreements and
understandings between the Parties hereto relating to the subject matter hereof.
8.11 Counterparts. This Agreement may be executed in counterparts, which, when
taken together, shall constitute one agreement.

          8.12 Amendments. This Agreement may not be amended, modified, altered
               ----------
or supplemented other than by means of a written instrument duly executed and
delivered on behalf of Seller and Purchaser.

                                      -11-
<PAGE>

     IN WITNESS WHEREOF, the Parties, by their duly authorized representatives,
have executed this Agreement as of the Effective Date.

E. HELLER & COMPANY                       THERASENSE, INC.

By:   /s/ Ephraim Heller                  By:  /s/ W. Mark Lortz
      ________________________________         _________________________________

Name:     Ephraim Heller                  Name:  W. Mark Lortz
      ________________________________          ________________________________

Title:    President                       Title: President
      ________________________________          ________________________________
<PAGE>

                                Schedule 2.1(a)

                           Transferred Technologies
                           ------------------------

                                      ***

*** Confidential treatment requested
<PAGE>

                                Schedule 2.1(b)

                                Excluded Assets
                                ---------------

                                      ***

*** Confidential treatment requested
<PAGE>

                                 Schedule 2.2

                              Assumed Liabilities
                              -------------------

                                      ***

*** Confidential treatment requested
<PAGE>

                                 Schedule 2.3

                             Excluded Liabilities
                             --------------------

                                      ***

*** Confidential treatment requested
<PAGE>

                                 Schedule 4.4

                       Title to Transferred Technologies
                       ---------------------------------

                                      ***

*** Confidential treatment requested<PAGE>

[CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS AGREEMENT HAVE
BEEN REDACTED AND HAVE BEEN SEPARATELY FILED WITH THE COMMISSION]

                                                                    Exhibit 10.7

                       COOPERATIVE DEVELOPMENT AGREEMENT

Parties:

Gainor Medical North America, LLC ("Gainor")    TheraSense, Inc. ("TheraSense")
2205 Highway 42 North                           1311 Harbor Bay Parkway
P.O. Box 353                                    Suite 2000
McDonough, Georgia 30253-0353                   Alameda, CA 94502
Attn: Bill Taylor                               Attn: Charlie Liamos
Phone: (770) 474-4414                           Phone: (510) 749-5436
Fax:  (770) 474-6214                            Fax:  (510) 749-5438

     This Agreement is entered into as of December 1, 1998 by and between
Gainor, a Georgia limited liability company, and TheraSense, a California
corporation,

                                   Recitals

     TheraSense has developed certain patented and non-patented technologies
related to measurement of glucose levels in humans.  Gainor is in the business
of designing and manufacturing microsampling products for use in connection with
measurement of glucose levels.  Gainor and TheraSense wish to enter into a
cooperative arrangement for the development of two new systems and related
marketable products for simplified measurement of glucose levels utilizing the
TheraSense technologies.

     The first system, referred to as ***, is intended to be a minimally
invasive monitoring technique utilizing an electrochemical method of measuring
blood glucose proprietary to TheraSense. This method requires a significantly
smaller blood sample than current technologies. Gainor will develop new
microsampling methods and devices for this system.

     The second system, referred to as ***, is intended to be a resident glucose
monitoring system utilizing an electrochemical device shallowly embedded in the
abdomen or other part of the body for constant monitoring of glucose levels:
Gainor will develop methods and devices for introducing the device into the
patient.

                                   Agreement

     In furtherance of the above goals, and in consideration of the mutual
covenants contained in this Agreement and other valuable consideration, the
receipt and sufficiency of which are acknowledged by the parties, Gainor and
TheraSense agree as follows:

     1.   Definitions.  The following terms as used in this Agreement shall
          -----------
have the following meanings:

          1.1  "Confidential Information" shall mean any competitively
                ------------------------
sensitive or secret business, marketing, financial or technical information of
Gainor or TheraSense, including the terms of this Agreement and all other
agreements and communications between Gainor and TheraSense.

*** Confidential treatment requested
<PAGE>

     Confidential Information shall not include information which is (i)
generally known to the public or readily ascertainable from public sources
(other than as a result of a breach of confidentiality hereunder), (ii)
independently developed by the receiving party without reference to or reliance
on any Confidential Information of the disclosing party, as demonstrated by
written records of the receiving party, or (iii) obtained from an independent
third party who created or acquired such information without reference to or
reliance on Confidential Information.

          1.2  "Products" shall mean all marketable products which result from
                --------
the Projects.

          1.3  "Projects" means the two new glucose monitoring systems
                --------
(including the Gainor Components) being developed by TheraSense, currently
referred to as *** and ***, as more particularly described in the Recitals above
and in the Project Plan.

          1.4  "Project Plan" is defined in Section 2.4.
                ------------

          1.5  "Project Managers" are defined in Section 2.2.
                ----------------

          1.6  "Steering Committee" is defined in Section 2.3.
                ------------------

          1.7  "Technology or Technologies" shall mean collectively all
                --------------------------
inventions, devices, processes, methods, techniques and associated intellectual
property rights.

          1.8  "Force Majeure" shall mean any act of God, earthquake, fire,
                -------------
natural disaster, accident, act of government, or an act that is beyond the
control of either party.

     2.   Development.
          -----------

          2.1  General.  Gainor shall work with TheraSense to develop certain
               -------
components (the "Gainor Components") of two new glucose monitoring systems being
developed by TheraSense, currently referred to as *** and ***.

          2.2  Project Managers.  Each party shall appoint a Project Manager,
               ----------------
who shall be responsible for managing the Project. The initial Project Managers
are listed on Exhibit A attached hereto.
              ---------

          2.3  Steering Committee.  In addition to the Project Managers, the
               ------------------
parties shall form a Steering Committee consisting of senior management of each
party. The Steering Committee shall be responsible for the success of the
Projects, resolve all disputes between the Project Managers, and approve all
changes to the Project Plan.

          2.4  Project Plan.  The Project Plan shall be attached to this
               ------------
agreement as Exhibit A.  The Project Plan shall set forth, at a minimum: a list
             ---------
of the Gainor Components; the development and management responsibilities of
each party; the development schedule for the Gainor Components and the projects;
the resources to be provided by each party (including personnel, facilities,
Technology and capital investment); the specifications for the Gainor
Components; and the budget for each of the Gainor Components setting forth
projected development costs, capital expenditures, projected sales,
manufacturing costs, and normal margins.

*** Confidential treatment requested

                                      -2-
<PAGE>

          2.5  Revision of Project Plan.  The Project Managers shall meet
               ------------------------
periodically at times and places to be mutually agreed upon, but no less than
once per quarter. The Project Plan may be amended from time to time to reflect
the results of such meetings, and as necessary from time to time to reflect
changes in Technology, development schedule, cost estimates, and other changes.
In the event of significant cost overruns or changes in the base assumptions
upon which the Project Plan was prepared, the development of the Gainor
Components will be reassessed and the Project Plan may be revised. Suggested
revisions to the Project Plan may only be submitted to the steering committee by
the mutual agreement of the Project Managers, who shall work together in good
faith to keep the Project Plan up to date and accurate. All amendments to the
Project Plan must be approved by the Steering Committee as evidenced by the
signature of each member of the Steering Committee on an amended Project Plan.

          2.6  Cooperation.  Unless or until a Project is discontinued as
               -----------
provided in Section 11 hereof, each party shall cooperate fully with the other,
and use its best efforts to further the development of the Gainor Components and
the Projects. Each party shall provide such information regarding preexisting
technologies as the other shall require to fulfill its obligations hereunder.

          2.7  Subcontracting.  Gainor may subcontract portions of its rights
               --------------
and responsibilities hereunder to ***, and/or *** but only to the extent
specifically set forth in the Project Plan.

          2.8   ***

          3.0   Manufacturing.  In exchange for its efforts under this
                -------------
Agreement, Gainor shall have the exclusive worldwide right for a period of seven
years from the date of this agreement to manufacture, or have manufactured, the
Gainor Components. Gainor and TheraSense shall work jointly to develop a control
plan for Gainor's manufacturing process to obtain process improvements with the
ultimate goal to achieve within reasonable economic limits process capability
index (Cpk) of 1.67 or higher on all key parameters of the Product
Specifications. Gainor agrees to implement process improvements and process
validations using Process Failure Mode Effect analysis (FMEA) for each step of
the process. *** Terms for manufacturing and distributing the Gainor Components
and other components to be produced by Gainor shall be set forth in a
manufacturing and supply agreement after the viability of each Project has been
proven from a technological and economic standpoint. Pricing for the Gainor
Components shall be as set forth in the project plan based on cost,
manufacturing equipment amortization, and normal Gainor margins. ***

*** Confidential treatment requested

                                      -3-
<PAGE>

     4.   Funding.  Each party will fund its own development efforts and pay
          -------
all of its own costs and expenses.  Each party will make such investments as
reasonably necessary to successfully complete each Project. Gainor shall arrange
for the capital necessary to develop manufacturing capacities for the Gainor
Components. Each party shall provide the other with such financial and technical
information regarding the Projects as the other shall reasonably request,
including: total expenditures incurred to date for the Projects; monthly and
quarterly budgets for future expenditures; and expected sources of funding and
financing for completion of the Projects. Upon request, TheraSense shall provide
Gainor with its most recent balance sheets showing capital available for
completion of the Projects.  ***

     5.   Marketing.  TheraSense or assigns, or marketing and/or distribution
          ---------
partners will be responsible for the marketing, sale and distribution of the all
Products.

     6.   Intellectual Property.  All Technologies owned or developed solely by
          ---------------------
a party and its employees and agents, whether prior to or subsequent to the date
of this Agreement, and all related intellectual property rights, shall remain
the exclusive property of such party.  Each party hereby grants the other such
rights and license in and to use such Technology as the other shall reasonably
require to exercise its rights and fulfill its obligations hereunder, including
the right of TheraSense to sell Products.  Technologies developed jointly by
Gainor and TheraSense shall be jointly owned.  This Section shall survive any
termination of this agreement.

     7.   Exclusivity.  TheraSense shall work exclusively with Gainor for
          -----------
development of the Gainor Components. Gainor shall not supply the Gainor
Components to any third party without the written consent of TheraSense. Neither
party shall use the jointly owned Technologies outside of the Projects(other
than pursuant to the sale of Products by TheraSense) without the written consent
of and Proper compensation to the other party. Notwithstanding the foregoing,
neither party shall be precluded from using the general know-how gained during
the development of the Projects under this Agreement. Gainor shall not be
precluded from developing any Technology for any third party, provided Gainor
does not use the Technology owned by TheraSense or the Intellectual Property
developed specifically for the Gainor Components.

*** Confidential treatment requested

                                      -4-
<PAGE>

     8.   Inventions, Patents and Trademarks.
          ----------------------------------

          8.1  Notice.  Each party shall promptly notify the other upon the
               ------
making, conceiving or reducing to practice of any patentable invention or
discovery related to the Projects.

          8.2  Right to Patent.  Each party shall have the sole right to
               ---------------
prepare, file, prosecute, maintain and extend patent applications and patents
concerning all patentable Technology owned by such party, as determined under
Section 6, provided each party shall give notice to the other of its intent to
patent any technology concerning the projects prior to filing. If such party
elects not to file, prosecute or maintain patent applications or ensuing patents
or certain claims encompassed by such patent applications or ensuing patents in
any country with respect to any invention or discovery related to the Projects,
then the other party may elect to do so on the developing party's behalf. Such
party shall give notice to the developer and owner of the patentable Technology
of its intent to so prepare, file and prosecute a patent, and the owner shall
have 30 days to choose to take such action on its own behalf, and take
significant action toward doing so. At the end of such notice period, if the
owner has not taken such action, the non-owner may do so.

          8.3  Joint Patents.  TheraSense and Gainor shall mutually agree upon
               -------------
which party shall be responsible to prepare, file, prosecute, maintain and
extend patent applications and patents concerning all patentable inventions and
discoveries owned jointly by Gainor and TheraSense. If the parties cannot agree,
then Gainor shall have the right to apply for such patents using counsel of its
choice, in consultation with TheraSense.

          8.4  Protection of Ability to Patent.  Neither party shall take any
               -------------------------------
action which would have a material adverse effect on the patentability of any
newly developed Technology or improvement to any Technology, including any
public sale or disclosure thereof, until the parties either file an application
or mutually agree not to pursue a patent.

     9.   Regulatory Approval.  TheraSense will be responsible for regulatory
          -------------------
approval of the Products, with such assistance from Gainor as TheraSense shall
reasonably request, on terms to be agreed upon.

     10.  Confidentiality.  Each party shall at all times keep confidential all
          ---------------
Confidential Information of the other.  Neither party shall permit or authorize
access to or disclosure of the other party's Confidential Information to any
person or entity other than (i) employees (including temporary contract
employees, engineers and developers) who have signed confidentiality agreements
with protection substantially similar to that contained in this Agreement and
professional advisors under a professional obligation of confidentiality
(including lawyers, accountants, financial advisors, and sources of funding)
with a "need to know" such information, (ii) independent contractors who have
signed confidentiality agreements with protection substantially similar to that
contained in this agreement, provided that each party shall have the right to
approve (approval not to be unreasonably withheld) in advance all contractors
who are given access to the Confidential Information of such party and (iii)
governmental regulatory authorities, to the extent required for compliance with
applicable laws, and subject to such protective measures as may be available to
preserve the confidentiality of such information following disclosure.  Each
party shall promptly

                                      -5-
<PAGE>

notify the other in writing of the existence of any unauthorized knowledge,
possession or use of the other party's Confidential Information by any person or
entity.

     11.  Termination.
          -----------

          11.1  Voluntary Termination.  Gainor may terminate its development
                ---------------------
obligations under this Agreement with respect to either or both Projects with 90
days written notice to TheraSense upon a reasonable determination by Gainor that
the resources required to develop the Gainor Components for such Project will
materially exceed the projections set forth in the Project Plan or has elected
not to enter into a manufacturing agreement for strategic reasons. (The
inability of Gainor and TheraSense to come to terms, i.e. price, etc., on a
manufacturing agreement is not considered a strategic reason for not entering
the agreement.) Upon such termination, (i) Gainor shall no longer be responsible
for development of the Gainor Components for such Project, (ii) In the case that
such termination occurs on or before August 31, 1999, TheraSense shall have the
right to Purchase a fully paid up license, for the purpose, of developing,
manufacturing and selling products which measure glucose (as distinct from micro
sampling products) all Gainor Technology developed prior to termination and all
jointly owned technology for a payment of *** (iii) In the case that termination
occurs after August 31, 1999, TheraSense may license from Gainor the technology
of Gainor required for TheraSense or its nominee to complete the Gainor
Components for such Project, (iv) Gainor shall be entitled to utilize *** the
Gainor Technology and jointly owned Technology developed prior to termination
for the purpose of developing, manufacturing and selling micro sampling products
(as distinct from products which measure glucose).

          11.2  Termination by TheraSense on Default of Gainor.
                ----------------------------------------------

                (a)  Gainor Event of Default.  The following shall constitute
                     -----------------------
an Event of Default by Gainor:

                     (i)    Gainor discontinues its development work on the
Gainor Components for either Project for any reason other than as set forth in
11.1 above.

                     (ii)   Gainor is unwilling or unable to complete the Gainor
Components for a Project or any Products substantially within the time periods
and budget set forth in the Project Plan.

                     (iii)  Gainor (prior to execution of a definitive
manufacturing and supply agreement) is unwilling or unable to manufacture and
supply the Gainor Components for completed products in the amounts, within the
quality or upon the time frame required to avoid a material adverse effect upon
TheraSense.

                     (iv)   Gainor otherwise materially breaches its obligations
hereunder.

               (b)   Result of Gainor Event of Default.  Upon an Event of
                     ---------------------------------
Default by Gainor, TheraSense shall provide written notice to Gainor of such
occurrence, and Gainor shall have 30 days to cure such problem or breach, or
reach a mutual agreement with TheraSense for

*** Confidential treatment requested

                                      -6-
<PAGE>

remedying same or this Agreement shall be terminated. Upon the expiration of
such 30 day period, if Gainor has not cured the Event of Default of otherwise
reached agreement with TheraSense, (i) TheraSense may continue development of
the Gainor Components on its own, or Contract for a third party to continue
development of the Gainor Components, (ii) TheraSense shall have the right to
use all Technologies developed and owned by Gainor for such discontinued Project
and all jointly owned Technologies developed for such Project to finish, use,
manufacture, market and distribute the Products. Gainor shall provide to
TheraSense such technical and other information regarding the Gainor Components,
including technical and development plans and documentation, as TheraSense may
require to exercise its rights under this Section. As an alternative to
terminating this Agreement, but without effecting the other rights granted in
the immediately proceeding sentence, following an Event of Default described in
Section 11.2(a)(iii). TheraSense may utilize additional suppliers to obtain
Gainor Components. TheraSense shall compensate Gainor for its work through such
termination at a reasonable royalty rate consistent with industry standards, and
the level of completion of the Gainor Components at such time.

          11.3  Termination by Gainor on Default of TheraSense.
                ----------------------------------------------

                (a)  TheraSense Event of Default.  The following shall
                     ---------------------------
constitute an Event of Default by TheraSense:

                     (i)    TheraSense discontinues either Project for any
reason.

                     (ii)   TheraSense is unwilling or unable to complete a
Project or any Products under a Project substantially within the time periods
and budget set forth in the Project Plan.

                     (iii)  TheraSense is unwilling or unable to manufacture,
market and distribute the Products within a reasonable amount of time following
completion of the Products and obtaining any necessary regulatory approvals.

                     (iv)   TheraSense otherwise materially breaches its
obligations hereunder.

               (b)   Result of TheraSense Event of Default.  Upon an Event of
                     -------------------------------------
Default by TheraSense, Gainor may terminate its obligations with respect to such
Project by providing written notice thereof to TheraSense, who shall have 30
days to cure such Event of Default, or reach a mutual agreement with Gainor for
remedying same or this agreement shall be terminated. Upon the expiration of
such 30 day period, if TheraSense has not cured the Event of Default of
otherwise reached agreement with Gainor, (i) Gainor shall have the right use all
Technologies owned by Gainor and all jointly owned Technologies developed for
such Project for any purpose with no further obligation to TheraSense, and (ii)
Gainor shall continue to have the exclusive right to manufacture the Gainor
Components if a Project ever produces marketable Projects. TheraSense shall
provide to Gainor such technical and other information regarding such Projects
and all related Products, including technical and development plans and
documentation, as Gainor may require to exercise its rights under this Section.
Gainor shall compensate TheraSense for use of jointly developed and owned
Technology used in any product completed and sold by Gainor at a reasonable

                                      -7-
<PAGE>

royalty rate consistent with industry standards based on the amount of such
Technology included in any such finished product.

     12.  Right to Perform.  Each party hereby represents to the other that it
          ----------------
has the necessary rights and licenses to enter into and perform under the terms
of this Agreement and to grant such rights and licenses as it has agreed to
grant hereunder. Each party shall notify the other promptly upon discovering
that any of its Technology related to the Projects is or may be infringing upon
the rights of any third party, and shall promptly notify the other if it
believes or receives notice that any third party is infringing on any its
technologies.

     13.  Indemnification.  Each party shall indemnify and hold the other party
          ---------------
harmless from and against any and all claims, judgments, liabilities and damages
arising out of (i) any claim that the Technology of the indemnifying party
infringes any patent, trade secret or other intellectual property right of a
third party or (ii) any negligent act, error or omission by the indemnifying
party, its employees, agents, servants or representatives in the performance of
its duties and obligations hereunder.  In the event any such claim is made, the
party to be indemnified (the "Indemnitee") shall immediately notify the
                              ----------
indemnifying party (the "Indemnitor").  The Indemnitor shall have the right to
control the defense of such claim with counsel of its choice and shall bear all
cost and expense of such defense.  The Indemnitee shall allow the Indemnitor to
control the defense of such claims, shall cooperate as reasonably necessary in
the defense of any such claim at the expense of the Indemnitor, and may
participate in the defense with counsel of its choice at Indemnitee's cost.  If
the Indemnitor fails to vigorously defend Indemnitee.  Indemnitee may assume
such defense with counsel of its own choice.  To the extent a claim is based on
infringement by Technology jointly owned by both parties, each party shall bear
the cost and expense of its own defense, and shall indemnify, reimburse and hold
the other party harmless to the extent that it is determined that such
infringement is not attributable to such other party or such other party's
Technology.

     14.  Dispute Resolution.
          ------------------

          14.1  Negotiation.  The Steering Committee shall negotiate in good
                -----------
faith to resolve any dispute under this Agreement. If the Steering Committee
cannot agree, the dispute shall be referred to appropriate senior management of
each party for resolution, and such senior management shall negotiate in good
faith to resolve such dispute.

          14.2  Arbitration.  If a claim, controversy or dispute between the
                -----------
parties cannot be resolved within a reasonable time period as set forth above,
either party may demand that such matter be submitted to final and binding
arbitration. Issuance of an arbitration demand shall suspend the effect of any
default entailed by such claim, controversy or dispute and any judicial or
administrative proceedings instituted in connection therewith, for the duration
of the arbitration proceedings. Arbitration shall be governed by the Commercial
Arbitration Rules of the American Arbitration Association (the "AAA").
Arbitration shall be conducted by three arbitrators. Each party shall choose one
arbitrator within 10 days of the arbitration demand. The final arbitrator shall
be chosen by the first two within 10 days of their appointment. If the first two
arbitrators cannot agree, the third arbitrator shall be chosen by AAA. The
arbitrator or arbitrators shall evaluate all outstanding claims and dispute,
determine the relative fault of each party, and deliver its or their decision
within 60 days of the date of receipt of the arbitration demand, specifying such
remedy

                                      -8-
<PAGE>

(including money damages) as shall (a) fully implement the intent and purposes
of this Agreement and (b) indemnify and hold harmless the non-breaching party
from all losses, costs and expenses (including costs of arbitration and
reasonable attorneys' fees) resulting from the default. Termination or
limitation of either party's rights to its Technology, or any associated
intellectual property rights may not be awarded under any circumstances. The
right to demand arbitration and to receive damages and obtain other available
remedies as provided hereunder shall be the exclusive remedy in the event an
arbitration demand is made. The parties hereby consent to the enforcement in the
courts of each state where each party resides or maintains assets of any
arbitral judgment or award rendered pursuant to this Section.

     15.  General.
          -------

          15.1  Notices.  Notices shall be deemed given as of receipt as shown
                -------
by the records of FedEx, UPS, registered US Mail, or other courier service, or
fax with a confirmation notice, if properly addressed as first set forth above.
Either party may change their address by notice in compliance with this section.

          15.2  Assignment.  This Agreement shall not be assignable by either
                ----------
party to any third party without the written consent of the other party hereto;
except that either party may assign this Agreement without the other party's
consent to an entity that acquires substantially all of the business or assets
of the assigning party whether by merger, transfer of assets, or otherwise. Upon
a permitting assignment of this Agreement, all references herein to the
assigning party shall be deemed references to the parry to whom the Agreement is
so assigned.

          15.3  Waiver.  The failure of either party to enforce any term of
                ------
this Agreement shall not constitute a waiver of either party's right to enforce
every term of this Agreement.

          15.4  Enforcement.  If either party brings an action under this
                -----------
Agreement (including appeal), the prevailing party shall be entitled to recover
reasonable attorneys' fees and costs.

          15.5  Enforceability.  Should any provision of this Agreement be held
                --------------
by a court of competent jurisdiction or arbitration authority to be
unenforceable, the remaining provisions of this Agreement shall not be affected
or impaired thereby except to the extent necessary to give effect, as close as
possible to the intent of the parties as expressed herein.

          15.6  Choice Of Law.  This agreement shall be governed by and
                -------------
construed under the laws of the state of Georgia, excluding its conflict of laws
rules.

          15.7  Force Majeure.  Neither party shall be in default by reason of
                -------------
any failure in the performance of this Agreement, other than a failure to make
payment when due or to comply with restrictions upon the use of the other's
Technology, if such failure arises out of any act, event or circumstance beyond
the reasonable control of such parry, whether or not otherwise foreseeable. The
party so affected will resume performance as soon as reasonably possible,

          15.8  Headings and Captions.  The headings and captions appearing in
                ---------------------
this Agreement are inserted only as a matter of convenience and in no way limit
the scope or affect the meaning of any section.

                                      -9-
<PAGE>

          15.9    Employees.  Neither party shall hire or solicit for hire any
                  ---------
employee of the other without the express written consent of the other party.

          15.10   Prior Agreements, Amendment.  This Agreement constitutes the
                  ---------------------------
entire agreement between the parties and supersedes all prior understandings and
agreements between them regarding the content hereof, and may not be modified or
amended except in writing signed by authorized representatives of both parties.

     IN WITNESS WHEREOF, the undersigned parties have executed this Agreement as
of the date first set forth above.

Gainor Medical North America, LLC          TheraSense, Inc.

By: /s/ Mark J. Gainor                     By: /s/ W. Mark Lortz
------------------------------------       ----------------------------------

Mark J. Gainor                             W. Mark Lortz
------------------------------------       ----------------------------------
____
Print Name                                 Print Name

Chairman & CEO                             President & CEO
------------------------------------       ----------------------------------
Print Title                                Print Title

12/18/98                                   12/17/98
------------------------------------       ----------------------------------
Date                                       Date

                                      -10-
<PAGE>

                                   EXHIBIT A

          TheraSense/Gainor Medical Cooperative Development Agreement
                                      ***

                                      ***

*** Confidential treatment requested
<PAGE>

                                   EXHIBIT A

          TheraSense/Gainor Medical Cooperative Development Agreement
                                      ***

                                      ***

*** Confidential tretment requested

                                      -2-
<PAGE>

                                   EXHIBIT A

          TheraSense/Gainor Medical Cooperative Development Agreement
                                      ***

                                      ***

This project plan has been reviewed and approved by:

/s/ Fred Colman                          12-17-98
----------------------------------       -------------------
Fred Colman                              Date
Vice President, Engineering
TheraSense, Inc.

/s/ Bill Taylor                          12-18-98
----------------------------------       -------------------
Bill Taylor                              Date
Director, Product Technology Group
Gainor Medical North America, LLC

*** Confidential treatement requested

                                      -3-
<PAGE>

                                   EXHIBIT A

          TheraSense/Gainor Medical Cooperative Development Agreement
                                      ***

                                      ***

*** Confidential treatment requested

                                      -4-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00027-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00027-of-00352.parquet"}]]